Immunotherapy in progressive supranuclear palsy

Current Opinion in Neurology
Pavan A Vaswani, Abby L Olsen

Abstract

Progressive supranuclear palsy (PSP) is a progressive adult-onset neurodegenerative disease. Abnormally, phosphorylated forms of the microtubule-associated protein tau containing four repeat domains (4R-tau) aggregate in neurons. Additionally, increasing evidence suggests that secretion and uptake of fragments of abnormal 4R-tau may play a role in disease progression. This extracellular tau is a natural target for immunotherapy. Three monoclonal antibodies targeting extracellular tau are in clinical stages of development. ABBV-8E12 and BIIB092 were safe in Phase 1, but both Phase two studies recently failed futility analyses. UCB0107 recently reported (in abstract form) Phase 1 safety results, and a Phase 2 study is under consideration. Stem cell therapy and the infusion of plasma are also being explored clinically. The likely role of extracellular tau in the progression of PSP makes tau a natural target for targeted immunotherapy. Clinical trials are still in early stages, and although tau immunotherapy has largely been shown to be safe, efficacy has yet to be demonstrated.

References

Jul 1, 1988·Neurology·L I GolbeR C Duvoisin
Jul 9, 2010·Current Opinion in Neurology·Dennis W DicksonKeith A Josephs
Sep 28, 2014·Proceedings of the National Academy of Sciences of the United States of America·Brandon B HolmesMarc I Diamond
Nov 6, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Gesine RespondekUNKNOWN Movement Disorder Society-endorsed PSP Study Group
Dec 3, 2014·Neurobiology of Aging·Jessica BrightIrene Griswold-Prenner
Dec 17, 2014·Neuropathology and Applied Neurobiology·G G Kovacs
Mar 31, 2015·Annals of Clinical and Translational Neurology·Kiran YanamandraDavid M Holtzman
Feb 18, 2016·Journal of Experimental Neuroscience·Martha A Kahlson, Kenneth J Colodner
Sep 7, 2016·JAMA Neurology·Jinte MiddeldorpTony Wyss-Coray
Oct 16, 2016·Neurology·Shubir DuttUNKNOWN AL-108-231 investigators
May 4, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Günter U HöglingerUNKNOWN Movement Disorder Society-endorsed PSP Study Group
May 14, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Jennifer L WhitwellUNKNOWN Movement Disorder Society-endorsed PSP Study Group
Jul 1, 2017·Molecular Neurodegeneration·Cheryl E G Leyns, David M Holtzman
Dec 21, 2017·Acta Neuropathologica Communications·Amrit MudherJean-Pierre Brion
Feb 20, 2018·Current Neurology and Neuroscience Reports·Melissa J Armstrong
Apr 18, 2018·Parkinsonism & Related Disorders·Vanessa FleuryPierre R Burkhard
May 29, 2018·Perspectives in Biology and Medicine·Leigh Turner
Jul 26, 2018·Frontiers in Cellular Neuroscience·Juan R PereaMarta Bolós
Sep 28, 2018·Nature·Douglas SippLeigh Turner
Nov 20, 2018·Frontiers in Neuroscience·Petr NovakMichal Novak
Dec 26, 2018·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Irfan A QureshiMichael Grundman
Feb 16, 2019·Acta Neuropathologica Communications·Santosh JadhavNorbert Zilka
Apr 23, 2019·Expert Opinion on Emerging Drugs·Nikolaos Giagkou, Maria Stamelou
May 1, 2019·Brain : a Journal of Neurology·Marie AlbertMorvane Colin
May 6, 2019·Mayo Clinic Proceedings·Nathan P StaffWolfgang Singer
May 16, 2019·Neural Regeneration Research·Edwin E Reza-ZaldivarAlejandro A Canales-Aguirre
Jun 17, 2019·Life Sciences·Forough Chakari-KhiaviMehdi Yousefi
Nov 19, 2019·Frontiers in Bioengineering and Biotechnology·Bárbara Mendes-PinheiroAntónio J Salgado

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.